This one is different from the rest of the shelf. It is a real, approved medicine, and that changes what is known about it, what it is called, and who is allowed to make it. Here is all of that without the jargon.
Tirzepatide, in plain words
Year of first approval, United States
2022
Approved as a medicine. Sold here as a research material.
Nauck and D’Alessio, Cardiovasc Diabetol 2022;21(1):169
Tirzepatide is an approved medicine. You may know it better by its brand names, Mounjaro and Zepbound.
That single fact makes it the odd one out here. It is worth knowing why before anything else.
After you eat, your gut releases hormones. They tell the pancreas and the brain what to do next. Drugs in this family copy those hormone signals.
They work by locking onto docking points on your cells. Those are called receptors. Picture a keyhole, and the drug as a spare key cut to fit it.
Tirzepatide fits two keyholes: GLP-1 and GIP. That is one more than semaglutide, which fits only GLP-1. It is one fewer than retatrutide, which fits three.
Two keyholes was the new idea when tirzepatide arrived. It was the first drug of its kind to reach approval.
Regulators in the United States, Europe and the UAE have approved tirzepatide for type 2 diabetes. It went through the full process. It has a licence.
That word gets thrown around loosely, so here is what it actually bought.
| Because it is approved | What that means |
|---|---|
| Large trials finished | Five big trials in diabetes, plus separate trials in weight, run to completion and published. |
| Heart safety reviewed | Cardiovascular risk was assessed across the whole trial programme, not guessed at. |
| Independent research followed | Universities now run their own studies on it. Roughly 2,477 papers exist, against 178 for retatrutide. |
| Known doses and warnings | There is an approved label saying who it is for and what to watch for. |
None of that exists for a compound still in trials. It is the difference between a finished thing and one that is not.
In the five main diabetes trials, at weekly doses of 5 to 15 mg, people saw their long-term blood sugar marker fall by between 1.24 and 2.58 percentage points. Average weight loss ran from 5.4 to 11.7 kg.
In those trials it beat semaglutide at 1.0 mg weekly, and beat adjusted background insulin, on both measures.
A separate Phase 3 weight trial in China, 210 adults over 52 weeks, reported average weight change of -13.6 percent at 10 mg and -17.5 percent at 15 mg. Placebo was -2.3 percent.
Mostly stomach and gut: nausea, vomiting, diarrhoea, constipation. More common at higher doses. This is the same pattern across this whole drug family.
This is what a completed programme gets you. Across the trials, heart-related events were formally reviewed. None of the measures showed higher risk than in the comparison groups. The results met the usual bar for heart safety.
No such review exists yet for retatrutide, because the trials that would produce one are still running.
Researchers still are not sure why the second keyhole helps. GIP reduces food intake in animals. That has not been shown the same way in people. So even for an approved drug with thousands of papers, part of the mechanism is unsettled. That is normal. It is also a useful reminder of how little is settled for the compounds that never got this far.
Tirzepatide is protected by patent. Eli Lilly developed it and holds the rights. The approved medicine, sold as Mounjaro and Zepbound, is made by them.
That has a consequence worth hearing plainly. It is also the most common challenge raised against this whole shelf.
Tirzepatide powder from any other source is not Mounjaro and not Zepbound. It has not been through the approval process. It is not covered by the licence, the label, or the safety monitoring that comes with an approved medicine.
Whatever a certificate shows, none of it turns the powder into the approved product. Those are two different things. Anyone blurring them is selling you a confusion.
You will also see the reverse argued. The drug is patented, so nothing sold outside the licensed supply can be real. That does not follow either. A patent governs who may make and sell a compound. It does not govern what a chemical is.
Which is why the paperwork question is the only one a supplier can answer. Not "is this the approved medicine", because it is not. Only "is this powder the compound the label claims, at the purity and amount claimed". An outside lab can settle that.
Seller terms / September 2026
Everything above happened in registered clinical trials. Those used drug made by the company that invented it. Exact doses. Screened patients. Doctors watching. Side effects recorded and reviewed.
Every one of those things is part of the result. A vial has none of them.
Not that something works. Not that it is safe. Those come from trials.
What can be proved is narrow. That the powder is the compound named on the label. At the purity stated, in the amount stated, from a batch you can trace. Checked by a lab that does not sell it to you.
A report worth anything names the laboratory, the batch, the purity and the amount, and carries a code you can check with that laboratory yourself.
Every seller looks the same on the good day. Four things decide what happens on the bad one, and all four are published before you order if you go and read them.
Read the seller's own published pages, not their marketing, and none of these terms were written by us.
The plain page on tirzepatide, plus the four things to check on a certificate before you buy any of it, from anyone.
You are on the list.
The sheet comes by email, as one page you can print.
It follows once our list is live, and nothing else is sent. We do not sell peptides and we are not going to email you about any.
One email with the sheet. Unsubscribe in one click. We do not share addresses.
Before you go
One sheet, in plain language, that you can run on any seller in any country. One column filled in from a published certificate, and one left empty for the seller you already have open.
You are on the list.
The sheet comes by email, as one page you can print.
Nothing else follows it. We do not sell peptides and we are not going to email you about any.
One email with the sheet. Unsubscribe in one click. We do not share addresses.